NextCure Advances SIM0505 and LNCB74 ADCs in Phase 1 Cancer Trials

Reuters

Jan 26

NextCure Advances SIM0505 and LNCB74 ADCs in Phase 1 Cancer Trials

NextCure Inc. has announced updates on its two antibody drug conjugate $(ADC)$ programs. For SIM0505, a CDH6-targeted ADC, data from the Phase 1 dose escalation study are anticipated to be presented in the second quarter of 2026. The study is evaluating SIM0505 in patients with advanced solid tumors, with a focus on gynecological cancers and platinum-resistant ovarian cancer. For LNCB74, a B7-H4-targeted ADC, dosing has commenced in higher dose cohorts in an ongoing Phase 1 dose escalation study following a recent protocol amendment. Proof-of-concept data for LNCB74, previously expected in the first half of 2026, has been delayed, and a trial progress update is now anticipated in the second half of 2026. No clinical study results have been presented to date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-006021), on January 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2606291456"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2606291456\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2606291456?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-26 14:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606291456","market":"fut","top_or_hot":-1,"title":"NextCure Advances SIM0505 and LNCB74 ADCs in Phase 1 Cancer Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NextCure Advances SIM0505 and LNCB74 ADCs in Phase 1 Cancer Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NextCure Inc. has announced updates on its two antibody drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> programs. For SIM0505, a CDH6-targeted ADC, data from the Phase 1 dose escalation study are anticipated to be presented in the second quarter of 2026. The study is evaluating SIM0505 in patients with advanced solid tumors, with a focus on gynecological cancers and platinum-resistant ovarian cancer. For LNCB74, a B7-H4-targeted ADC, dosing has commenced in higher dose cohorts in an ongoing Phase 1 dose escalation study following a recent protocol amendment. Proof-of-concept data for LNCB74, previously expected in the first half of 2026, has been delayed, and a trial progress update is now anticipated in the second half of 2026. No clinical study results have been presented to date.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-006021), on January 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NextCure Advances SIM0505 and LNCB74 ADCs in Phase 1 Cancer Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNextCure Advances SIM0505 and LNCB74 ADCs in Phase 1 Cancer Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-26 14:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NextCure Advances SIM0505 and LNCB74 ADCs in Phase 1 Cancer Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NextCure Inc. has announced updates on its two antibody drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> programs. For SIM0505, a CDH6-targeted ADC, data from the Phase 1 dose escalation study are anticipated to be presented in the second quarter of 2026. The study is evaluating SIM0505 in patients with advanced solid tumors, with a focus on gynecological cancers and platinum-resistant ovarian cancer. For LNCB74, a B7-H4-targeted ADC, dosing has commenced in higher dose cohorts in an ongoing Phase 1 dose escalation study following a recent protocol amendment. Proof-of-concept data for LNCB74, previously expected in the first half of 2026, has been delayed, and a trial progress update is now anticipated in the second half of 2026. No clinical study results have been presented to date.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-006021), on January 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NXTC","symbol_name":"Nextcure Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL1mLXsP:1","article_id":"2606291456","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606291456","pubTimestamp":1769410534,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NextCure Inc. has announced updates on its two antibody drug conjugate  programs. For SIM0505, a CDH6-targeted ADC, data from the Phase 1 dose escalation study are anticipated to be presented in the second quarter of 2026. The study is evaluating SIM0505 in patients with advanced solid tumors, with a focus on gynecological cancers and platinum-resistant ovarian cancer. For LNCB74, a B7-H4-targeted ADC, dosing has commenced in higher dose cohorts in an ongoing Phase 1 dose escalation study following a recent protocol amendment. Proof-of-concept data for LNCB74, previously expected in the first half of 2026, has been delayed, and a trial progress update is now anticipated in the second half of 2026. No clinical study results have been presented to date.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NXTC":"Nextcure Inc.","BK4139":"生物科技"},"translate_title":"NextCure在1期癌症试验中推进SIM0505和LNCB74 ADC","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NXTC":0.9},"content_text":"NextCure Advances SIM0505 and LNCB74 ADCs in Phase 1 Cancer Trials\n    \n\n        NextCure Inc. has announced updates on its two antibody drug conjugate $(ADC)$ programs. For SIM0505, a CDH6-targeted ADC, data from the Phase 1 dose escalation study are anticipated to be presented in the second quarter of 2026. The study is evaluating SIM0505 in patients with advanced solid tumors, with a focus on gynecological cancers and platinum-resistant ovarian cancer. For LNCB74, a B7-H4-targeted ADC, dosing has commenced in higher dose cohorts in an ongoing Phase 1 dose escalation study following a recent protocol amendment. Proof-of-concept data for LNCB74, previously expected in the first half of 2026, has been delayed, and a trial progress update is now anticipated in the second half of 2026. No clinical study results have been presented to date.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-006021), on January 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}